Reuters logo
BRIEF-Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot
2017年6月21日 / 下午4点47分 / 5 个月前

BRIEF-Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot

June 21 (Reuters) - Indivior Plc :

* Indivior Plc presents results from the phase 3 pivotal study of RBP-6000 buprenorphine monthly depot for the treatment of opioid use disorder

* Indivior Plc - 24-week study met its primary and key secondary endpoints for both dosage regimens of RBP-6000

* Indivior - Clinical data from phase 3 study also showed outcomes with RBP-6000 are consistent across other secondary clinical endpoints versus placebo

* Indivior - In study, RBP-6000 generally well tolerated, safety profile consistent with that of transmucosal buprenorphine with no unexpected safety findings Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below